Pfizer has gained FDA approval for Eucrisa, a new eczema treatment which could achieve peak annual sales of $2 billion a year. The drug is significant because it is the first non-steroidal therapy for ...

Credit: Pfizer. Eucrisa is a topical phosphodiesterase 4 inhibitor. The prescribing information for Eucrisa ® (crisaborole) ointment has been updated to include data related to long-term, once daily ...

Pfizer Inc. PFE announced that the FDA has approved a supplemental new drug application (sNDA) for its eczema drug, Eucrisa (crisaborole) ointment, 2%. The sNDA sought label expansion of Eucrisa for ...

FDA issues statement on Eucrisa for eczema In a controlled trial, participants receiving Eucrisa achieved clear or almost clear skin after 28 days of treatment. The FDA has approved Eucrisa ...

Eucrisa is a brand-name form of the generic medication crisaborole. Doctors prescribe it in topical form to help manage mild to moderate eczema. It belongs to a drug class called phosphodiesterase 4 ...

EUCRISA™ is a new, steroid-free, topical ointment for mild to moderate atopic dermatitis (eczema) 1 First prescription treatment indicated for mild to moderate AD to be approved in more than 10 years ...

Pfizer once harbored blockbuster hopes for Eucrisa to be the next big topical treatment for inflammatory skin diseases. But the ointment never gained traction thanks to side effects and reimbursement ...

Pfizer Inc. PFE announced top-line results from a late-stage study, which evaluated its PDE4 inhibitor, Eucrisa (crisaborole ointment, 2%), for the treatment of mild to moderate atopic dermatitis (AD) ...

Pfizer has gained FDA approval for Eucrisa, a new eczema treatment which could achieve peak annual sales of $2 billion a year. The drug is significant because it is the first non-steroidal therapy for ...

Pfizer Inc. PFE announced that the FDA has approved a supplemental new drug application (sNDA) for its eczema drug, Eucrisa (crisaborole) ointment, 2%. The sNDA sought label expansion of Eucrisa for ...